The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TRDA | -59.45% | N/A | N/A | -71% |
| S&P | +19.89% | +109.18% | +15.89% | +49% |
Entrada Therapeutics, Inc. operates as a biotechnology company. It focuses on delivery of biomolecules into the cell to treat devastating diseases. The firm offers intracellular enzyme replacement therapy and protein-protein interaction inhibitors programs. The company focuses on creating and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases. Entrada Therapeutics was founded by Dehua Pei in September 22, 2016 and is headquartered in Boston, MA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.95M | -97.9% |
| Gross Profit | $0.85M | -99.1% |
| Gross Margin | 43.59% | -55.5% |
| Market Cap | $255.05M | -51.8% |
| Market Cap / Employee | $1.39M | 0.0% |
| Employees | 183 | 15.1% |
| Net Income | -$43.10M | -178.3% |
| EBITDA | -$43.85M | -180.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $72.48M | -60.9% |
| Accounts Receivable | $1.18M | -84.6% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $49.28M | -11.8% |
| Short Term Debt | $5.46M | -36.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -14.23% | -33.6% |
| Return On Invested Capital | -22.56% | 9.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$29.76M | -176.7% |
| Operating Free Cash Flow | -$29.49M | -174.0% |
| Metric | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 4.82 | 10.03 | 9.07 | 11.18 | -50.50% |
| Price to Book | 1.38 | 1.53 | 0.79 | 0.61 | -65.62% |
| Price to Sales | 3.02 | 3.53 | 2.16 | 3.50 | 65.38% |
| Price to Tangible Book Value | 1.38 | 1.53 | 0.79 | 0.61 | -65.62% |
| Price to Free Cash Flow TTM | 3.75 | - | |||
| Enterprise Value to EBITDA | -12.58 | -78.68 | -2.20 | 0.49 | -73.58% |
| Free Cash Flow Yield | 26.6% | - | |||
| Return on Equity | 16.4% | 19.6% | 7.2% | -18.1% | -155.26% |
| Total Debt | $61.31M | $59.21M | $57.00M | $54.74M | -15.05% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
